Overexpressed IncRNA FTX promotes the cell viability, proliferation, migration and invasion of renal cell carcinoma via FTX/miR-4429/UBE2C axis

ZHIPPING CHEN¹, MENGTING ZHANG², YUKANG LU², TAO DING¹, ZHANYU LIU¹, YANMEI LIU¹, ZHAOLING ZHOU¹ and LANFENG WANG³

¹Department of Laboratory Medicine, First Affiliated Hospital of Gannan Medical University; ²Department of The First Clinical Medical College, Gannan Medical University; ³Department of Nephrology, First Affiliated Hospital of Gannan Medical University, Zhanggong, Ganzhou, Jiangxi 341000, P.R. China

Received October 21, 2021; Accepted May 17, 2022

DOI: 10.3892/or.2022.8378

Abstract. The present study aimed to explore the role of long non-coding (Inc)RNA FTX and ubiquitin-conjugating enzyme E2C (UBE2C) in promoting the progression of renal cell carcinoma (RCC) and the underlying regulatory mechanism. Relative levels of IncRNA FTX, UBE2C, AKT, CDK1 and CDK6 in RCC cell lines were detected by reverse transcription-quantitative (RT-q) expression levels of UBE2C, phosphorylated (p)-AKT/AKT, p-CDK1/CDK1 and p-CDK6/CDK6 in RCC and paracancerous specimens and RCC cells were measured by western blot or immunohistochemistry assay. In addition, the proliferative rate, cell viability, cell cycle progression, migratory rate and invasive rate of RCC cells overexpressing IncRNA FTX by lentivirus transfection were determined by a series of functional experiments, including the colony formation assay, MTT assay, flow cytometry, Transwell assay and wound healing assay. The targeted binding relationship in the IncRNA FTX/miR-4429/UBE2C axis was validated by dual-luciferase reporter assay. By intervening microRNA (miR)-4492 and UBE2C by the transfection of miR-4429-mimics or short interfering UBE2C-2, the regulatory effect of IncRNA FTX/miR-4429/UBE2C axis on the progression of RCC was evaluated. Finally, a xenograft model of RCC, the mice implanted with RCC cells overexpressing IncRNA FTX showed a larger tumor size and higher tumor weight than those of controls, while the in vivo knockdown of UBE2C significantly reduced the size of RCC lesions, indicating the reversed cancer-promoting effect of IncRNA FTX. Overall, the present study showed that IncRNA FTX was upregulated in RCC and could significantly promote the proliferative, migratory and invasive capacities, enhancing the viability and accelerating the cell cycle progression of RCC cells by exerting the miRNA sponge effect on miR-4429 and thus upregulating UBE2C. IncRNA FTX and UBE2C are potential molecular biomarkers and therapeutic targets of RCC.

Introduction

Renal cancer is among the top ten malignant tumors in the world, with 400,000 newly diagnosed cases annually (1). Renal cell carcinoma (RCC) is a malignant tumor that originates in the renal tubular epithelium, accounting for >90% of renal cancer cases (2) and its incidence has gradually increased in recent years (3). Although great strides have been made on medical techniques where local RCC can be surgically resected with a five-year overall survival of 76% (4), health management of metastatic RCC is quite challenging in clinical practice (5). The occurrence and development mechanism of RCC is closely linked to the epigenetics, tumor heterogeneity and carcinogenesis, immune infiltration and microenvironment (6), with ~3% of cases having a family history (7). A number of genes perform an abnormal expression in RCC, such as the von Hippel-Lindau (VHL), which is often inactivated in sporadic RCC by mutation or promoter hypermethylation (8),
and BAP-1, which has important implications for utilization of molecular testing, prognosis, future therapeutics and distinguishing clear cell (cc)RCC from other RCC (8,9). Therefore, early diagnosis and active development of effective therapeutic targets have great significance to the research and clinical diagnosis and treatment of RCC.

IncRNAs are noncoding RNAs >200 nucleotides long, serving as key regulators in the physiological and pathological processes of human beings (10). Increasing amounts of evidence has shown that abnormally expressed IncRNAs in RCC are crucially involved in cancer development and progression (11-14). IncRNA FTX is upregulated in adenocarcinoma and gastric cancer, indicating that IncRNA FTX is an oncogene (15,16). He et al (17) report that IncRNA FTX is upregulated in RCC as an oncogene and its knockdown inhibits the migratory and invasive capacities of RCC cells. However, the specific molecular mechanism of IncRNA FTX in the malignant progression of RCC remains to be elucidated.

Ubiquitin conjugating enzyme E2 C (UBE2C) is a component of the ubiquitin proteasome system. As an essential factor of the cell cycle regulatory E3, human anaphase promoting complex/cyclosome (APC/C), UBE2C participates in the ubiquitination modification of cyclins and mitosis-related factors, thereby accelerating cell mitosis (18). Previous studies have shown that the mRNA or protein level of UBE2C is abnormally upregulated in a number of types of cancers with poor clinical outcomes, including liver cancer, lung cancer, gastric cancer, colon cancer and cervical cancer (19). UBE2C is a vital gene involved in the development of RCC and is significant to mediate the proliferation and migration of RCC cells (20). However, the molecular mechanism between IncRNA FTX and UBE2C in regulating the development of RCC remains to be elucidated.

In the present study, by detecting the expression levels of IncRNA FTX in the clinical specimens of RCC, it was found that FTX was significantly upregulated. Furthermore, IncRNA FTX was predicted using the StarBase to exert the miRNA sponge effect on miR-4429 to upregulate UBE2C. The present study further analyzed the in vitro and in vivo functions of IncRNA FTX in RCC by intervening the expression levels of IncRNA FTX, miR-4429 and UBE2C in RCC cells and establishing a xenograft model of RCC in nude mice to explore the potential signaling and mechanisms of IncRNA FTX/miR-4429/UBE2C axis.

Materials and methods

Sample collection. A total of six pairs of RCC and paracancerous specimens that were ≤4 cm away from the margin of RCC lesions were collected from patients with RCC (male to female ratio: 2:1) who were surgically treated in the First Affiliated Hospital of Gannan Medical University. All were patients with RCC hospitalized in the First Affiliated Hospital of Gannan Medical University hospital between March and June 2020 and aged 48-60 years-old, with the median as 53. Renal cancer tissues and adjacent tissues were removed after surgical treatment without radiotherapy or chemotherapy. The fresh tissues were immediately stored in liquid nitrogen and stored in a refrigerator at -80˚C after removal and then used for reverse transcription-quantitative (RT-q) PCR, western blotting or immunohistochemistry (IHC). The specimens were fixed in 4% paraformaldehyde for 24 h at a room temperature and dehydrated and transparentized with gradient concentrations (30, 50, 75, 95 and 100%) of ethanol and xylene, and then embedded in paraffin at 55˚C to prepare 4-μm tissue sections. and some fresh specimens were subjected to the isolation of total RNA and proteins for RT-qPCR and western blotting, respectively. The present study was approved by Ethics Review Committee of Scientific Research of Gannan Medical College (number 2020007). All patients who participated were informed of the content of the study and their written informed consent was obtained.

Cell culture. RCC cell lines, including A498 (cat. no. BNCC338630; BeNa Culture Collection), A704 (cat. no. BNCC342393; BeNa Culture Collection), SN12C (cat. no. BNCC341858; BeNa Culture Collection), 769-P (cat. no. BNCC101643; BeNa Culture Collection), the human renal fibroblast cell line KFB (cat. no. HTX2520; Otwo Biotech), human proximal convoluted tubular cell line HK-2 (cat. no. BNCC338012; BeNa Culture Collection) and the 293T cell line (cat. no. MZ-0005; Ningbo Mingzhou Biotechnology Co., Ltd.) were used. Briefly, the cells were seeded in a 10-mm culture dish and cultivated in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin and streptomycin in a humidified incubator containing 5% CO2 and 95% air at 37˚C.

Cell transfection. miR-4429-mimics (5’-AAA AGCUGU GCUGAGAGGCG-3’) and mimic-negative control (NC; 5’-AAGUGUCACCGAUCAAGCG-3’; Ribobio Co., Ltd., Guangzhou, China) and shUBE2C-1, shUBE2C-2, shUBE2C-3 and the empty vector was used as a shNC (Shanghai GeneChem Co., Ltd.) were used in cell transfection performed following the recommendations of Lipofectamine® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Briefly, the cells were seeded in a 12-well plate at a density of 5x104 cells/well and cultured to 80% of confluence. After 4-h starvation in serum-free DMEM (Gibco; Thermo Fisher Scientific), 100 nM miR-4429-mimics, mimic-NC or 2 μg shUBE2C was incubated with Lipofectamine® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) for 20 min, followed by incubation with cells for 40 min at a room temperature. Fresh serum-containing DMEM (Gibco; Thermo Fisher Scientific) was replaced at 24 h and the transfection efficacy was evaluated by RT-qPCR.

RT-qPCR. The cells were cultured at 80% of confluence for RNA extraction. RNA extraction, cDNA synthesis and qPCR were all performed according to the manufacturer’s protocols. Briefly, the total RNAs in cells were isolated using TRIzol® (Thermo Fisher Scientific, Inc.) and 1 μg of the total RNA was reversely transcribed to cDNA using a Takara PrimeScript RT reagent kit. Subsequently, qPCR was performed using a SYBR Premix Ex Taq II with Tli RNaseH (Takara Bio, Inc.) on an ABI Prism 7500 system (Thermo Fisher Scientific, Inc.). In brief, the total RNA induced with gDNA eraser and reversely transcribed to cDNA in 42˚C for 15 min and then subjected to thermal cycles at 95˚C for 15 min, followed by 40 cycles at 95˚C for
5 sec, 60°C for 30 sec and 72°C for 40 sec and finally annealing at 72°C for 10 min. The relative level was calculated using the 2^{-ΔΔCq} method with GAPDH or U6 as the internal reference (21). All the experiments were performed in triplicate and repeated three times. The primer sequences are shown in Table I.

**Western blotting.** The total proteins in RCC cells or homogenate tissues were isolated using RIPA buffer (Beyotime Institute of Biotechnology) containing PMSF and a protease inhibitor. Protein concentrations were measured using a BCA protein assay kit (Beyotime Institute of Biotechnology). Later, 50 µg of protein sample was loaded on 10% SDS-PAGE and transferred on PVDF membranes at 300 mA. Nonspecific antigens on PVDF membranes were blocked by immersing in TBST (1% Tween) containing 5% skimmed milk in room temperature for 1 h. After immunoblotting with primary antibodies (1:1,000) at 4°C overnight and secondary antibodies (1:1,000) at room temperature for 1 h. Finally, the membrane was treated with chemiluminescent horse radish peroxidase (HRP) substrate (cat. no. WBKLS0500; MilliporeSigma) to visualize the protein bands and exposure was performed using a Bio-Rad Universal Hood II Gel Doc Imaging system (Bio-Rad Laboratories, Inc.) and the grey value was analyzed using ImageJ 1.8.0.112 (National Institutes of Health). The antibodies used in this study were purchased from ABclonal Biotech Co., Ltd. and the catalog numbers were: UBE2C (cat. no. A5499), AKT (cat. no. A17909), phosphorylated (p)-AKT (cat. no. AP0140), CDK1 (cat. no. A0220), p-CDK1 (cat. no. AP0016), CDK6 (cat. no. A16357), p-CDK1 (cat. no. AP0326), GAPDH (cat. no. A19056) and the secondary antibody HRP Rabbit Anti-Goat IgG (H+L) (cat. no. AS029).

**Immunohistochemistry (IHC).** The RCC sections were incubated in xylene (15 min x3), dehydrated in anhydrous ethanol (5 min x2), 85% ethanol (5 min x1) and 75% ethanol (5 min x1) and washed in ddH2O. Antigen retrieval was performed by pouring citrate buffer (pH 6.0; Sangon Biotech Co., Ltd.; cat. no. E673000) on the sections at room temperature for 15 min. After incubation in 3% H2O2 in the dark at 37°C for 25 min and blocking in 3% BSA (Sangon Biotech Co., Ltd.; cat. no. E661003) at 37°C for 30 min, the sections were incubated with primary antibodies at 4°C overnight. On the next day, they were washed in PBS (pH 7.4, 5 min x3) and incubated with HRP-labeled secondary antibodies at room temperature for 2 h. Later, the sections were counterstained with DAB and hematoxylin at room temperature for 3 min. After dehydration in ddH2O, the sections were stained using the H&E staining kit (Sangon Biotech Co., Ltd.; cat. no. E607318). Briefly, the sections were stained with hematoxylin for 5 min. After differentiation and bluing, the sections were washed in ddH2O, dehydrated in 85% and 5% ethanol sequentially and stained with eosin for 5 min. All the staining was carried out in a room temperature. Finally, they were incubated in anhydrous ethanol for three times, xylene twice and mounted using neutral gum for observation under a light microscope (XSP-8CA; Shanghai Optical Instrument Co. Ltd.), five fields of view were randomly selected for each tissue section and observed at x100 magnification.

**Hematoxylin & Eosin (H&E) staining.** RCC specimens were fixed in 4% paraformaldehyde for 24 h at room temperature and dehydrated and transparentized with gradient concentrations (30, 50, 75, 95 and 100%) of ethanol and xylene, and then embedded in paraffin at 55°C to prepare 4-µm tissue sections for preparing tissue sections. Later, the sections were incubated in xylene (20 min x2), anhydrous ethanol (5 min x2) and 75% ethanol (5 min x1). After washing in ddH2O, the sections were stained using the H&E staining kit (Sangon Biotech Co., Ltd.; cat. no. E607318). Briefly, the sections were stained with hematoxylin for 5 min. After differentiation and bluing, the sections were washed in ddH2O, dehydrated in 85% and 5% ethanol sequentially and stained with eosin for 5 min. All the staining was carried out in a room temperature. Finally, they were incubated in anhydrous ethanol for three times, xylene twice and mounted using neutral gum for observation under a light microscope (XSP-8CA; Shanghai Optical Instrument Co. Ltd.), five fields of view were randomly selected for each tissue section and observed at x100 magnification.

| Genes       | Sequences                                      |
|-------------|-----------------------------------------------|
| lncRNA FTX-F | 5'-GTGTCTCTCTCTCTCTCTCTCTT-3'                 |
| lncRNA FTX-R | 5'-CCTCTTCTCTCTCTCTCTCTCTT-3'                 |
| miR-4429-F  | 5'-GGGAGAAAAGCTGGGCTGAG-3'                    |
| miR-4429-R  | 5'-GGCCAGGCAGTCGTAGTTG-3'                    |
| UBE2C-F     | 5'-CTGCCCGAGCTCTGAAAAAC-3'                   |
| UBE2C-R     | 5'-AGGAAAAATTTAAAGACGACAAG-3'                |
| Akt-F       | 5'-CCTGAAAGCTACTGGGCAAGG-3'                  |
| Akt-R       | 5'-AACAAGCGAGGCGGCTG-3'                      |
| CDK1-F      | 5'-CCTAGCATCCCATGTCAAAACTTG-3'               |
| CDK1-R      | 5'-TGATTCATGCCTTGGGCAAACCTTG-3'              |
| CDK6-F      | 5'-TGCACAGTGTCACGAAACAGA-3'                  |
| CDK6-R      | 5'-ACCTCGAGAGAGCAGAACA-3'                    |
| GAPDH-R     | 5'-AGAAGGCTGGGCTCATTT-3'                     |
| U6-F        | 5'-CTCCTTCTCGGAGACAGACACA-3'                 |
| U6-R        | 5'-AACCGCTTCACAAATTCTCGT-3'                  |

lncRNA, long non-coding RNA; miR, microRNA; UBE2C, ubiquitin-conjugating enzyme E2C; F, forward; R, reverse.
sequentially and permeabilization in xylene (5 min x1) at room temperature, neutral gum was used for mounting. The positive staining of cells was observed under a light microscope (XSP-SCA; Shanghai Optical Instrument Co. Ltd.), five fields of view were randomly selected for each tissue section and observed at x100 magnification. The antibodies used in this experiment were purchased from AbClonal Biotech Co., Ltd. and the catalog numbers were: UBE2C (cat. no. A54999) and the secondary antibody (cat. no. AS029).

**Lentivirus infection.** The GV367 plasmid (Shanghai GeneChem Co., Ltd.) was cut by AgeI/NheI and then the FTX sequence or short hairpin (sh)FTX, shUBE2C1, shUBE2C2, shUBE2C3 sequences were spliced to produce overexpressed lentivirus plasmids GV367-FTX and knocked down plasmids GV367-shFTX (Shanghai GeneChem Co., Ltd.), while the non-spliced GV367 was used as a blank control (sequences were as listed: shFTX: 5'-CTGTCTACGACACTGAATTC-3'; shUBE2C1: 5'-CTTGCAAGAAACCTACTCTAAA-3'; shUBE2C2: 5'-CTTCTAGGAAACCACA-3'; shUBE2C3: 5'-TGATGTCCAGACATTCTCCTGG-3'; and the shNC: 5'-AATTCTCCGAACGTGTCAGT-3'). Lentivirus packaging was performed using the second-generation lentivirus packaging kit (GeneChem) at 37°C 15 min. The lentiviral aging was performed using the second-generation lentivirus ultracentrifugation at 70,000 x g at 4°C for 2 h. The supernatant was used for infection of the target cells.

Inhibition of ROS inductions by GSH was determined by pretreatment with 5 mM GSH for 3 h alone and then in combination with 2.5 μM CDODA-Me at 37°C for 3 h. Cells were then incubated with 10 μM DCF-DA at 37°C for 30 min (at 2 h and 30 min to 3 h treatment time point) at 37°C. Attached and floating cells were then harvested by trypsinization and pelleted by centrifugation at 3,500 x g at 4°C for 5 min. The cells were then resuspended in ice-cold PBS and DCF-DA fluorescence was detected using the FL1 channel of an FC500 flow cytometer (FACSCalibur; BD Biosciences). All experiments were performed in triplicate; data were analyzed using Cell Quest software version (Molecular Devices, LLC, version 5.1) and were shown as means ± SEMs.

**Colony formation assay.** Cells were seeded in a 6-well plate at a density of 5x10^4 cells/well and cultured for 15 days. Visible colonies were fixed in 4% paraformaldehyde and stained using 0.2% crystal violet at 37°C. The number of colonies (>50 cells) in three replicates per sample was calculated. Images of colonies were captured under an inverted microscope.

**MTT assay.** The cells were seeded in a 96-well plate at a density of 3x10^4 cells/well in 200 μl of DMEM. Briefly, 15 μl of MTT solution (15 mg/ml, Sangon Biotech Co., Ltd.; cat. no. A600799) was added at 6, 12, 18, 24, 30 and 36 h for 4-h cell culture at 37°C. After lysing in 150 μl of DMSO for 10 min at room temperature, the optical density at 490 nm was measured using an HBS-1101 microplate reader (DeTie).

**Flow cytometry for detecting cell cycle progression.** The cell cycle progression in RCC cells was measured using a Cell Cycle Staining kit (Sangon Biotech Co., Ltd.; cat. no. E607212). Briefly, the cells were washed in PBS, fixed in 70% ice-cold ethanol and incubated using a commercial kit in the dark at room temperature for 30 min. Cell cycle progression was measured using FC500 flow cytometer (FACSCalibur; BD Biosciences) and analyzed using FlowJo v10 (FlowJo LLC).

**Wound healing assay.** The A498 and A704 cells were seeded in a 12-well plate at a density of 1x10^5 cells/well. A 1 ml sterile pipette tip was used to make an artificial wound on a cell monolayer and then FBS-free DMEM was replaced. At 0, 12 and 24 h, cell migration was observed using an inverted microscope and assessed by calculating the cell-free zone using ImageJ 1.8.0.112 software (National Institutes of Health, Bethesda).

**Transwell assay.** Matrigel (Corning Life Sciences; cat. no. 354234) diluted in serum-free DMEM at a ratio of 1:5 was precoated on the Transwell insert at 37°C and dried for 4 h. Cell suspension was prepared in serum-free DMEM at 1x10^5 cells/ml and 200 μl of suspension was added on the top chamber and 500 μl of DMEM containing 10% FBS was added on the bottom. After cell culture for 24 h, the cells on the top chamber were wiped off using a cotton swab. The penetrating cells were fixed in 4% paraformaldehyde at room temperature for 20 min and stained using crystal violet at room temperature for 10 min. After washing and air drying, the cells were observed under a light microscope (XSP-SCA; Shanghai Optical Instrument Co. Ltd.) and the migratory cells were calculated in five randomly selected fields per well.
Complementary sequences in the UBE2C 3'UTR and the mimics or mimic-NC and Lipofectamine® were mixed. The aforementioned vectors were mixed with the mimos or mimics-NC and Lipofectamine® (Invitrogen; Thermo Fisher Scientific, Inc.) for 20 min at room temperature. Then, the cells were cotransfected with wild-type/mutant-type plasmid and miR-4429-mimics/mimics-NC, respectively, at 37°C in a humidified atmosphere containing 5% CO2 for 48 h, the plasmids were transfected at 500 ng per well and the final concentration of mimic or mimic-NC was 20 nM. Relative Firefly and Renilla luciferase activities were measured using a Dual-Luciferase Reporter Gene Assay kit (Promega Corporation). Relative luciferase activity was expressed as the ratio of firefly luciferase activity to Renilla luciferase activity.

**Xenograft model of RCC in nude mice.** A total of 18 BALB/c male nude mice (5-6 weeks old; ~15 g; Guangdong Medical Laboratory Animal Center) were habituated in a specific pathogen-free (SPF) environment with 12-h light/dark cycle, at 22±2°C and in a humidity 30‑70%. They had free access to food and water. A suspension of RCC cells in PBS was prepared. Prior to inoculation, the cell suspension was mixed with Matrigel (Corning Life Sciences; cat. no. B639281). WT plasmid pGL3-FTX-WT and Mut plasmid pGL3-FTX-Mut were similarly constructed. The aforementioned vectors were mixed with the mimics or mimics-NC and Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) for 20 min at room temperature. Then, the cells were cotransfected with wild-type/mutant-type plasmid and miR-4429-mimics/mimics-NC, respectively, at 37°C in a humidified atmosphere containing 5% CO2 for 48 h, the plasmids were transfected at 500 ng per well and the final concentration of mimic or mimic-NC was 20 nM. Relative Firefly and Renilla luciferase activities were measured using a Dual-Luciferase Reporter Gene Assay kit (Promega Corporation). Relative luciferase activity was expressed as the ratio of firefly luciferase activity to Renilla luciferase activity.

Statistical analyses. Statistical analysis was performed using GraphPad Prism 8 (GraphPad Software, Inc.). Data were normally distributed and are presented as the mean ± SEM. Comparisons between multiple groups were analyzed using one-way ANOVA followed by Tukey’s post hoc test or Bonferroni correction. All experiments were performed in triplicate and repeated three times. P<0.05 was considered to indicate a statistically significant difference.
that there is a signaling lncRNA FTX/miR-4429/UBE2C in RCC.

Knockdown of UBE2C effectively reverses the role of lncRNA FTX in promoting the malignant phenotype of RCC cells. shUBE2C-1, shUBE2C-2, shUBE2C-3 and shNC were synthesized and their transfection efficacies were detected. RT-qPCR and western blotting confirmed the best transfection efficacy of shUBE2C-2 (Fig. 5A and B). Subsequently, the RCC cells were co-transfected with si-UBE2C-2 and overexpression plasmid of lncRNA FTX. A series of functional experiments further indicated that the knockdown of UBE2C effectively reversed the enhanced proliferative, migratory and invasive capacities, viability and accelerated the cell cycle progression in RCC cells overexpressing lncRNA FTX (Figs. 5C-E and 6A and B). In addition, the expression of lncRNA FTX, miR-4429, UBE2C and the upregulated phosphorylation levels of AKT, CDK1 and CDK6 by the overexpression of lncRNA FTX were downregulated by the knockdown of UBE2C (Fig. 7A and B). It was suggested that lncRNA FTX promoted the progression of RCC by exerting the miRNA sponge effect on miR-4429, thus upregulating UBE2C.

lncRNA FTX significantly affects the size and differentiation of subcutaneous RCC in nude mice. A-498 cells with lncRNA FTX overexpression or knockdown by lentivirus transfection were first subjected to RT-qPCR for validating the transfection efficacy (Fig. 8A). The transfected A-498 cells cultured to 80% confluence were subcutaneously injected into nude mice. The mice were sacrificed at day 30 for collecting tumor tissues. Compared with those of controls, the subcutaneous tumor tissues were larger and heavier in mice implanted with A-498 cells overexpressing lncRNA FTX, while those with lncRNA FTX knockdown had smaller and lighter subcutaneous tumor
tissues (Fig. 8B and C). Tumor tissues were then prepared for sections and isolation of the total RNA and protein. It was found that the mRNA levels of lncRNA FTX and UBE2C were upregulated and miR-4429 was downregulated in subcutaneous tumor tissues collected from mice implanted with A-498 cells overexpressing lncRNA FTX. The mRNA and protein levels of UBE2C were upregulated. In mice implanted with A-498 cells with lncRNA FTX knockdown, downregulated UBE2C was detected in subcutaneous tissues (Fig. 8D-H). It was concluded that the in vivo overexpression of lncRNA FTX significantly influenced the expression level of UBE2C and the phosphorylation of AKT and CDK6 in
CHEN et al: OVEREXPRESSED lncRNA FTX UPREGULATES UBE2C

Discussion

RCC is a globally prevalent type of cancer. More than 140,000 deaths of RCC are reported every year, ranking 13th among the cancer mortality in the world (22). Although the early nonmetastatic RCC can be surgically treated, the recurrence rate of RCC is ≤40%. Metastatic RCC has a poor prognosis and low survival rate (23). Novel biomarkers for RCC microenvironment and immunotherapy have been widely analyzed. Targeted drugs including sunitinib (24) and bevacizumab (25) that inhibit VEGF and its receptor VEGFR, sirolimus (26) that...
Figure 4. LncRNA FTX exerts the miRNA sponge effect on miR-4429 to upregulate UBE2C. (A) Prediction of the relevance among lncRNA FTX, miR-4429 and UBE2C; (B) Double luciferase activity detection between lncRNA FTX and miR-4429; (C) Double luciferase activity detection between miR-4429 and UBE2C; (D) Transfection efficiency of lentivirus that overexpress FTX; (E) Relative miR-4429 expression in RCC cell lines that overexpressed FTX; (F) Relative UBE2C mRNA expression in RCC cell lines that overexpressed FTX; (G) UBE2C expression in RCC cell line that overexpressed FTX; (H) Transfection efficiency of miR-4429 mimics; (I) Relative UBE2C mRNA expression in RCC cell lines transfected with miR-4429 mimics; (J) UBE2C expression in RCC cell line transfected with miR-4429 mimics. *P<0.05; **P<0.01; ***P<0.001; NS, not significant; lncRNA, long non-coding RNA; miR, microRNA; UBE2C, ubiquitin-conjugating enzyme E2C; RCC, renal cell carcinoma; NC, negative control.
Figure 5. Knockdown of UBE2C effectively reverses the role of lncRNA FTX in the proliferation, viability, and cell cycle progression of RCC cells. (A) Transfection efficiency of lentivirus. (B) UBE2C expression of RCC cell lines. (C) Colony formation of RCC cell lines that overexpressed FTX or knocked down UBE2C. (D) Cell viability of RCC cell lines that overexpressed FTX or knocked down UBE2C. (E) Cell cycle distribution of RCC cell lines that overexpressed FTX or knocked down UBE2C. *P<0.05; **P<0.01; ***P<0.001; NS, not significant; UBE2C, ubiquitin-conjugating enzyme E2C; RCC, renal cell carcinoma; FTX, long non-coding RNA FTX; sh, short hairpin."
inhibits mTOR and nivolumab (27) used in immune therapies have been used for the treatment of metastatic RCC. It is important to actively search for new biomarkers and therapeutic targets of RCC.

lncRNA FTX has been extensively evaluated as a vital regulator of cancer cells. Chen et al (28) report that FTX is abnormally overexpressed in osteosarcoma (OS) tissues and cells that promote the proliferation and invasion and inhibits the apoptosis of OS cells by regulating the miR-214-5p/SOX4 axis, indicating that FTX might be a potential therapeutic target for OS. Zhao et al (29) show that lncRNA FTX promotes the progression of colorectal cancer (CRC) by regulating the miR-192-5p/EIF5A2 axis as an oncogene, providing new insights into the pathogenesis of CRC. Jin et al (30) reveal a novel ceRNA axis FTX/miR-200a-3p/FOXA2 in lung cancer cells, validating the therapeutic potential of FTX in lung cancer. In addition, FTX is upregulated in liver cancer, RCC, glioma and hematological cancer (31) and the regulatory effects of FTX on the invasion and migration of RCC cells has been confirmed (17). The present study consistently showed the presence of upregulated lncRNA FTX in RCC specimens. In addition, it showed that the overexpression of lncRNA FTX promoted the proliferation, cell cycle progression, migration and invasion of RCC cells and upregulated UBE2C, p-AKT, p-CDK1 and p-CDK6. In addition, the in vivo overexpression of lncRNA FTX in RCC cells significantly enlarged the size and increased the weight of subcutaneous tissues in nude mice. Taken together, the findings demonstrated the vital function of lncRNA FTX in aggravating the progression of RCC.

miRs have been previously confirmed to regulate the expression levels of RCC-related proteins, which serve as effective biomarkers for diagnosing, accurately determining the molecular classification and predicting the prognosis of RCC (32). miR-4429 is widely involved in the progression of various types of tumors. Wang et al (33) found that miR-4429 inhibits the growth of prostate cancer cells by downregulating DLX1 and inactivating the Wnt/β-catenin pathway. Li et al (34) demonstrated that miR-4429 blocks the proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) process of CRC cells by targeting FOXM1 to downregulate SMAD3. Cai et al (35) confirm that the silencing of lncRNA SNHG12 and overexpression of miR-4429 significantly inhibit the proliferation, migration and invasion of RL95-2 cells by downregulating MMP2 and MMP9 and targeting of the SNHG12/miR-4429 axis and can be used as a potential therapeutic target for endometrial cancer in the future. Pan et al (36) also report that miR-4429 suppresses ccRCC tumor progression and EMT by targeting CDK6. The present

Figure 6. Knockdown of UBE2C effectively reverses the role of lncRNA FTX in the migration and invasion of RCC cells. (A) Migration ability of RCC cell lines that overexpressed FTX or knocked down UBE2C (magnification, x100); (B) Invasive ability of RCC cell lines that overexpressed FTX or knocked down UBE2C (magnification, x100). *P<0.05; **P<0.01; NS, not significant; RCC, renal cell carcinoma; FTX long non-coding RNA FTX; UBE2C, ubiquitin-conjugating enzyme E2C; t, time.
Figure 7. Knockdown of UBE2C effectively reverses the role of IncRNA FTX in gene expression of RCC cells. (A) Relative RNA expression of RCC cell lines that overexpressed FTX or knocked down UBE2C. (B) Relative proteins expression of RCC cell lines that overexpressed FTX or knocked down UBE2C. *P<0.05; **P<0.01; ***P<0.001; NS, not significant; RCC, renal cell carcinoma; FTX long non-coding RNA FTX; UBE2C, ubiquitin-conjugating enzyme E2C; p-, phosphorylated; sh, short hairpin.
Figure 8. LncRNA FTX significantly affects the size and differentiation of subcutaneous RCC in nude mice. (A) Transfection efficiency of lentivirus; (B) Weight of tumor tissues; (C) Diameter of tumor tissues; (D) Relative LncRNA FTX expression in mice-tumor tissues; (E) Relative miR-4429 expression in mice-tumor tissues; (F) Relative UBE2C mRNA expression in mice-tumor tissues; (G) Relative UBE2C protein expression in mice-tumor tissues; (H) IHC of UBE2C in mice-tumor tissues (magnification, x100). *P<0.05; **P<0.01; ***P<0.001; NS, not significant; LncRNA, long non-coding RNA; UBE2C, ubiquitin-conjugating enzyme E2C; sh, short hairpin.
study predicted and later confirmed that IncRNA FTX significantly targeted miR-4429 and the latter could specifically bind to UBE2C 3'UTR using an online tool and dual-luciferase reporter assay, respectively. IncRNA FTX overexpression was able to downregulate miR-4429 and enhance the transcription level of UBE2C. In addition, the overexpression of miR-4429 significantly reversed the promotive effect of IncRNA FTX on the progression of RCC and expression level of UBE2C. It is suggested that the regulatory function of IncRNA FTX in the malignant progression of RCC depends on the miRNA sponge effect on miR-4429 to upregulate UBE2C.

UBE2C has been widely studied in cancers due to its carcinogenic effect. Wang et al (37) found that UBE2C is highly expressed in gastric cancer tissues. Silencing of UBE2C not only inhibits the colony formation of gastric cancer cells, but also DNA biosynthesis. In addition, miR-300 inhibits the progression of gastric cancer by reducing the abundance of UBE2C mRNA. Hu et al (38) report that the knockdown of UBE2C inhibits the proliferation and invasion of prostate cancer cells, which is a direct target of miR-381-3p. Icaritin downregulates UBE2C and upregulates miR-381-3p in human prostate cancer cells. Zhang et al (39) confirm that UBE2C is upregulated in rectal cancer and that the knockdown of UBE2C significantly inhibits the growth of xenograft tumor in mice. Previous studies support the oncogenic role of UBE2C in RCC, although the specific mechanism remains to be elucidated (20,39). The present study also identified upregulated UBE2C in RCC specimens. Notably, the knockdown of UBE2C effectively reversed the promoted proliferation, viability, cell cycle progression, migration and invasion induced by the overexpression of IncRNA FTX, as well as upregulating p-AKT, p-CDK1 and p-CDK6. It is suggested that UBE2C was responsible for aggravating the malignant progression of RCC through the FTX/miR-4429/UBE2C axis. In addition, implantation of A-498 cells overexpressing IncRNA FTX in nude mice resulted in enlarged subcutaneous tissues with heavier tumor weight compared with those of controls. IncRNA FTX also regulated UBE2C, p-AKT, p-CDK1 and p-CDK6 in subcutaneous tissues. Taken together, the in vivo findings indicate that IncRNA FTX significantly influenced the UBE2C level and phosphorylation of AKT, CDK1 and CDK6 and promoted the carcinogenesis of implanting A-498 cells in nude mice. The effects of IncRNA FTX in promoting the malignant phenotype of RCC could be significantly reversed by knockdown of UBE2C, which indicated that the axis IncRNA FTX/miR-4429/UBE2C could significantly influence the proliferation, viability, cell cycle progression, migration and invasion of RCC cells and hence are promising biomarkers and therapeutic targets for RCC.

In general, the present study examined the abnormally high expression of IncRNA FTX in RCC, its promoting effects and mechanism on RCC malignant phenotype. The results showed that IncRNA FTX could significantly promote the cell viability, proliferation, migration and invasion of RCC. IncRNA FTX acted as a molecular sponge of miR-4429 and promoted the process of RCC through the FTX/miR-4429/UBE2C axis. However, due to the limited number of the clinical samples, the correlation of clinical data could not be well demonstrated, which might be the main limitation of the present study. In addition, the present study did not test the expression level of apoptosis-related genes, which would be another limitation and a future research perspective.

In brief, IncRNA FTX and UBE2C are significantly upregulated in RCC specimens. Through the miRNA sponge effect on miR-4429 to upregulate UBE2C, IncRNA FTX markedly promoted the proliferation, viability, cell cycle progression, migration and invasion of RCC cells, thus aggravating the malignant progression of RCC. The findings indicated that IncRNA FTX and UBE2C are promising biomarkers and therapeutic targets for RCC.

Acknowledgements
Not applicable.

Funding
The present study was supported by Natural Science Foundation of Jiangxi Province (grant nos. 20192BAB205075 and 20202BAB106191), Scientific research project of Gannan Medical University (grant no. ZD201830) and Youth project of Jiangxi Provincial Department of Education (grant no. GJJ201544).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
ZC, and LW made substantial contributions to the conception or design of the work and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy and integrated of any part of the work are appropriately investigated and resolved. ZC, MZ and YuL performed the experiments. TD, ZL and LW performed the acquisition, analysis, and interpretation of data. TD, YaL and ZZ drafted the manuscript and revised it critically for important intellectual content; ZC and LW confirm the authenticity of all the raw data; all the authors approved the final version to be published.

Ethics approval and consent to participate
This research was approved by the Ethics Review Committee of Scientific Research of Gannan Medical College (approval number 2020075).

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, Rawla P and Barsouk A: Epidemiology of renal cell carcinoma. World J Oncol 21: 110, 2021.
2. Shen H, Luo G and Chen Q: Long noncoding RNAs as tumorigenic factors and therapeutic targets for renal cell carcinoma. Cancer Cell Int 21: 110, 2021.
3. Sun M, Thuret R, Abdollah F, Lughazzani G, Schmitges J, Tian Z, Shariat SF, Montorsi F, Patroni J, Perrotte P and Karakiewicz PI: Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: A trend analysis. Eur Urol 59: 135-141, 2011.

4. Weyerer V, Strissel PL, Stohr C, Eckstein M, Wach S, Taubert H, Brandl L, Geppert CI, Wullich B, Cynis H, et al: Endogenous Retroviral-K envelope is a novel tumor antigen and prognostic indicator of renal cell carcinoma. Front Oncol 11: 657187, 2021.

5. Taccioni EMC, Tuthill M and Protheroe A: Review of adjuvant therapies in renal cell carcinoma: Evidence to date. Onco Targets Ther 13: 12301-12316, 2020.

6. Hsieh JJ, Purdie MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal cell carcinoma. Nat Rev Dis Primers 3: 17009, 2017.

7. Maher ER: Hereditary renal cell carcinoma syndromes: Diagnosis, surveillance and management. World J Urol 36: 1891-1898, 2018.

8. Gallian AJ, Parilla M, Segal J, Ritterhouse L and Antic T: BAP1-Mutated clear cell renal cell carcinoma. Am J Clin Pathol 155: 718-726, 2021.

9. Kim BJ, Kim JH, Kim HS and Zang DY: Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: A meta-analysis and review. Oncotarget 8: 13979-13985, 2017.

10. Ciomborowska-Basheer J, Staszk A, Kubiak MR and Makalowska I: Not so dead genes-retrocopies as regulators of their disease-related progenitors and hosts. Cells 10: 912, 2021.

11. Li Q, Tian Y, Hu G, Liang Y, Bai W and Li H: Highly expressed antisense noncoding RNA in the INK4 locus promotes growth and invasion of renal clear cell carcina via the β-catenin pathway. Onco Targets Ther 13: 2677-2688, 2020.

12. Wang G, Li H and Hou Y: LncRNA MAGI2-AS3 inhibits tumor progression and angiogenesis by regulating ACY1 via interacting with transcription factor HEY1 in clear cell renal cell carcinoma. Cancer Gene Ther 29: 585-596, 2021.

13. Cheng T, Shuang W, Ye D, Zhang W, Yang Z, Fang W, Xu H, Gu M, Xu W and Guan C: SNHG16 promotes cell proliferation and inhibits cell apoptosis via activation of the miR-1303-p/STAR9 axis in clear cell renal cell carcinoma. Cell Signal 84: 110013, 2021.

14. Zhang J, Jin S, Xiao W, Zhu X, Jia C and Lin Z: Long noncoding RNA LINCO00641 promotes renal cell carcinoma progression via sponging microRNA-340-5p. Cancer Cell Int 21: 210, 2021.

15. Zhang F, Wang XS, Tang B, Li PA, Wen Y and Yu PW: Long non-coding RNA FTX promotes gastric cancer progression by targeting mir-215. Eur Rev Med Pharmacol Sci 24: 3037-3048, 2020.

16. Hao X, Wang H, Huo B, Wang L, Yang K, Wang J, Wang L and Wang H: FTX promotes cell proliferation and migration in lung adenocarcinoma via targeting miR-335-5p/NUPCB2 axis. Cancer Cell Int 20: 89, 2020.

17. He X, Sun F, Guo F, Wang K, Gao Y, Feng Y, Song B, Li W and Li Y: Knockdown of long noncoding RNA FTX inhibits proliferation, migration, and invasion in renal clear cell carcinoma cells. Oncol Res 25: 157-166, 2017.

18. Hao Z, Zhang H and Cowell J: Ubiquitin-conjugating enzyme UBE2C: Molecular biology, role in tumorigenesis, and potential as a biomarker. Tumour Biol 33: 723-730, 2012.

19. Xie C, Powell C, Yao M, Wu J and Dong Q: Ubiquitin-conjugating enzyme E2C: A potential cancer biomarker. Int J Biochem Cell Biol 47: 113-117, 2014.

20. Chen Z and Wang L: The clinical significance of <en>UBE2C</en> gene in progression of renal cell carcinoma. Eur J Histochem 65: 3196, 2021.

21. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔCT) Method. Methods 25: 402-408, 2001.

22. Capitanio U, Bensalah K, Bex A, Borjiani SA, Bray F, Coleman J, Gore JL, Sun M, Wood C and Russo P: Epidemiology of renal cell carcinoma. Eur Urol 75: 74-84, 2019.

23. Larroquete M, Peyraud F, Domblides C, Lefort F, Bernhard JC, Ravaud A and Gross-Goupil M: Adjuvant therapy in renal cell carcinoma: Current knowledge and future perspectives. Cancer Treat Rev 97: 102207, 2021.

24. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylak C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007.

25. Escudier B, Puzanska A, Karalesiew P, Ravaud A, Bracarda S, Szczylak C, Chevreau C, Filipek M, Melichar B, Bajetta E, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370: 2103-2111, 2007.

26. Yang S, de Souza P, Alemao E and Purvis J: Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. Br J Cancer 102: 1456-1460, 2010.

27. Motzer RJ, Escudier B, McDermott DF, Arén Ofronter O, Melichar B, Powles T, Donskov F, Plimack ER, Barthelény P, Hammers JH, et al: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer 8: e000891, 2020.

28. Chen H, Liu T, Ouyang H, Lin S, Zhong H, Zhang H and Yang Y: Upregulation of FTX promotes osteosarcoma tumorigenesis by increasing SOX4 expression via miR-214-5p. Onco Targets Ther 13: 7125-7136, 2020.

29. Zhao K, Ye Z, Li Y, Li C, Yang X, Chen Q and Xing C: LncRNA FTX contributes to the progression of colorectal cancer through regulating miR-192-5p/ElF5A2 axis. Onco Targets Ther 13: 2677-2688, 2020.

30. Jin S, He J, Zhou Y, Wu D, Li J and Gao W: LncRNA FTX activates FOXA2 expression to inhibit non-small-cell lung cancer proliferation and metastasis. J Cell Mol Med 24: 4839-4849, 2020.

31. Lin Y, Sheng Y, Chen J, Hu C, Zhou Z and Yuan C: The function of LncRNA FTX in several common cancers. Curr Pharm Des 27: 2381-2386, 2021.

32. Tsaiakimaki P, Giaginis C, Kontos CK and Scorilas A: Clinical utility of microRNAs in renal cell carcinoma: Current evidence and future perspectives. Expert Rev Mol Diagn 18: 981-991, 2018.

33. Wang J, Xie S, Liu J, Li T, Wang W and Xie Z: MicroRNA-4429 suppresses proliferation of prostate cancer cells by targeting distal-less homebox 1 and inactivating the Wnt/β-catenin pathway. BMC Urol 21: 40, 2021.

34. Li H, Liang W, Zhang H, Shui Y and Zhang Z: MicroRNA-4429 restrains colorectal cancer cell invasion and migration via regulating SMAD3-induced epithelial-mesenchymal transition. J Cell Physiol 236: 5875-5884, 2021.

35. Cai P, Wu M, Zhang B, Wu S, Wei H and Wei L: Long noncoding RNA SNHG12 regulates cell proliferation, invasion and migration in endometrial cancer by targeting miR4429. Mol Med Rep 22: 2842-2850, 2020.

36. Pan H, Hong Y, Yu B, Li L and Zhang X: miR-4429 inhibits tumor progression and epithelial-mesenchymal transition via targeting CDK6 in clear cell renal cell carcinoma. Cancer Biother Radiopharm 34: 334-341, 2019.

37. Wang Y, Huang F, Liu M and Zhao Q: UBE2C mRNA expression controlled by miR-300 and HuR determines its oncogenic role in gastric cancer. Biochem Biophys Res Commun 534: 597-603, 2021.

38. Hu J, Wu X, Yang C, Rashid K, Ma C, Hu M, Ding Q and Jiang H: Anticancer effect of icaritin on prostate cancer via regulating miR-381-3p and its target gene UBE2C. Cancer Med 8: 7833-7845, 2019.

39. Zhang Y, Tian S, Li X, Ji Y, Wang Z and Liu C: UBE2C promotes rectal carcinoma via miR-381. Cancer Biol Ther 19: 230-238, 2018.